PHAL: Phal-501 clinical prep and rights issue mark key steps as losses narrow and CleanTech gains traction

About this update from Pharmalundensis Ab

Net loss narrowed year-over-year as PharmaLundensis advanced Phal-501 to clinical readiness and prepared a 9.1 MSEK rights issue to fund trials and commercialization, while CleanTech projects attracted international interest.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Pharmalundensis Ab